書籍詳細

招待講演

P.5 掲載の参考文献

• 1) Brock JH:The physiology of lactoferrin. Biochem Cell Biol 80(1):1-6, 2002.
  pubmed

• 2) Legrand D, Elass E, Carpentier M, Mazurier J:Lactoferrin:a modulator of immune and inflammatory responses. Cell Mol Life Sci 62(22):2549-2559, 2005.
  pubmed

• 3) Valenti P, Antonini G:Lactoferrin:an important host defence against microbial and viral attack. Cell Mol Life Sci 62(22):2576-2587, 2005.
  pubmed

• 4) Yamauchi K, Wakabayashi H, Shin K, Takase M:Bovine lactoferrin:benefits and mechanism of action against infections. Biochem Cell Biol 84(3):291-296, 2006.
  pubmed

• 5) Teng CT:Lactoferrin gene expression and regulatoin:an overview. Biochem Cell Biol 80(1):7-16, 2002.

• 6) Ward PP, Paz E, Conneely OM:Multifunctional roles of lactoferrin:acritical overview. Cell Mol Life Sci 62(22):2540-2548, 2005.

• 7) Tsuda H, Sekine K, Fujita K, Iigo M:Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol 80(1):131-136, 2002.

• 8) Teng CT:Factors regulating lactoferrin geneexpression. Biochem Cell Biol 84(3):263-267, 2006.

• 9) Grant DJ, Shi H, Teng CT:Tissue and site-specific methylation correlates with expression of the mouse lactoferrin gene. J Mol Endocrinol 23(1):45-55, 1999.

• 10) Teng C, Gladwell W, Raphiou I, Liu E:Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals 17(3):317-323, 2004.
  pubmed

• 11) Razin A, Cedar H:DNA methylation and gene expression. Microbiol Rev 55(3):451-458, 1991.
  pubmed

• 12) Li S, Washburn KA, Moore R, Uno T et al. :Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res 57(19):4356-4359, 1997.

• 13) Shi H, Teng C:Promoter-specific activation of mouse lactoferrin gene by epidermal growth factor involves two adjacent regulatory elements. Mol Endocrinol 10(6):732-741, 1996.
  pubmed

• 14) Teng CT, Beard C, Gladwell W:Differential expression and estrogen response of lactoferrin gene in the female reproductive tract of mouse, rat, and hamster. Biol Reprod 67(5):1439-1449, 2002.
  pubmed

• 15) Teng CT, Gladwell W, Beard C, Walmer D et al. :Lactoferrin gene is estrogen responsive in the endometrium of human and rhesus monkey. Mol Human Reprod 8:58-67, 2002.
  pubmed

• 16) Teng CT:Lactoferrin gene promoter in human and mouse. Analogous and dissimilar characteristics. Adv Exp Med Biol 357:183-196, 1994.
  pubmed

• 17) Yang N, Shigeta H, Shi H, Teng C:Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. J Biol Chem 271(10):5795-5804, 1996.
  pubmed

• 18) Stokes K, Alston-Mills, B Teng C:Estrogen response element and the promoter context of the human and mouse lactoferrin genes influence estrogen receptor alpha-mediated transactivation activity in mammary gland cells. J Mol Endocrinol 33(2):315-334, 2004.

• 19) Geng K, Li Y, Bezault J, Furmanski P:Induction of lactoferrin expression in murine ES cells by retinoic acid and estrogen. Exp Cell Res 245(1):214-220, 1998.
  pubmed

• 20) Lee MO, Liu Y, Zhang XK:A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. Mol Cell Biol 15 (8):4194-4207, 1995.
  pubmed

• 21) Fillebeen C, Mitchell V, Dexter D, Benaissa M, et al. :Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Mol Brain Res 72(2):183-194, 1999.
  pubmed

• 22) Zhang Z, Teng CT:Methoxychlor stimulates the mouse lactoferrin gene promoter through a GC-rich element. Biochem Cell Biol 80(1):23-26, 2002.

• 23) Zheng J, Ather JL, Sonstegard TS, Kerr DE:Characterization of the infection-responsive bovine lactoferrin promoter. Gene 353(1):107-117, 2005.
  pubmed

• 24) Ward PP, Mendoza-Meneses M, Mulac-Jericevic B, Cunningham GA et al. :Restricted spatiotemporalexpression of lactoferrin during murine embryonic development. Endocrinology 140(4):1852-1860, 1999.

特別講演

P.15 掲載の参考文献

• 1) Reiter B, Brock JH, Steel ED:Inhibition of Escherichia coli by bovine colostrum and postcolostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli. Immunology 28:83-95, 1975.

• 2) 清澤 功:母乳の栄養学. 金原出版, 1998.

• 3) Fischbach MA, Lin H, Liu DR, Walsh CT:How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nature Chem Biol 2:132-138, 2006.

• 4) 茂木立志:構造解析から明らかになったβバレル蛋白質のさまざまな生物機能. 蛋白質・核酸・酵素 50:1460-1467, 2005.
  Medical*Online

• 5) Baker EN, Baker HM, Kidd RD:Lactoferrin and transferrin:functional variations on a commonstructural framework, Biochem. Cell Biol 80:27-34, 2002.
  pubmed

• 6) Aisen P, Leibman A:Lactoferrin and transferrin:a comparative study. Biochim Biophys Acta 257:314-323, 1972.
  pubmed

• 7) Shimazaki K, Oota K Nitta K, Ke Y:Comparative study of the iron-binding strengths of equine, bovine and human lactoferrins. J Dairy Res 61:563-566, 1994
  pubmed

• 8) Mazurier J, Spik G:Comparative study of the ironbinding properties of human transferrins. 1. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim Biophys Acta 629:399-408, 1980.

• 9) Shimazaki K:Lactoferrin:Amarvelous protein in milk? Chikusan Gakkai-ho 71:329-347, 2000.

• 10) Kim WS, Rahman Md M, Shimazaki K:Antibacterial activity and binding ability of bovine lactoferrin against Pseudomonas spp. J Food Safety, (in press).

• 11) Yu RH, Schryvers AB:Bacterial lactoferrin receptors:insights from characterizing the Moraxella bovis receptors. Biochem Cell Biol 80:81-90, 2002.
  pubmed

• 12) Ellison RT, Giehl TJ, LaForce, FM:Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56:2774-2781, 1988.
  pubmed

• 13) van Berkel PH, Geerts ME, van Veen HA, Mericskay M, de Boer HA et al. :N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J 328:145-151, 1997.
  pubmed

• 14) Sallmann FR, Baveye-Descamps S, Pattus F, Salmon V, Branza N et al. :Porins OmpC and PhoE of Escherichia coli as specific cell-surface targets of human lactoferrin. Binding characteristics and biological effects. J Biol Chem 274:16107-16114, 1999.
  pubmed

• 15) Plaut AG:The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol 37:603-622, 1983.
  pubmed

• 16) Hendrixson DR, Qiu J, Shewry SC, Fink DL, Petty S et al. :Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins atarginine-rich sites. Mol Microbiol 47:607-617, 2003.
  pubmed

• 17) Mitoma M, Oho T, Shimazaki Y, Koga T:Inhibitory effect of bovine milk lactoferrin on the interaction between a streptococcal surface protein antigen and human salivary agglutinin. J Biol Chem 276:18060-18065, 2001.
  pubmed

• 18) Shi Y, Kong W, Nakayama K:Human lactoferrin binds and removes the hemoglobin receptor protein of the periodontopathogen Porphyromonas gingivalis. J Biol Chem 275:30002-30008, 2000.
  pubmed

• 19) Singh PK, Parsek MR, Greenberg EP, Welsh MJ:Acomponent of innate immunity prevents bacterial biofilm development. Nature 417:552-555, 2002.

• 20) Perraudin JP, Prieels JP:Lactoferrin binding to lysozyme-treated Micrococcus luteus. Biochim Biophys Acta 718:42-48, 1982.
  pubmed

• 21) Li YM, Tan AX, Vlassara H:Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Medicine 1:1057-1061, 1995.

• 22) Watanabe T, Nagura H, Watanabe K Brown WR:The binding of human milk lactoferrin to immunoglobulin A. FEBS Lett 168:203-207, 1984.
  pubmed

• 23) Soares RV, Lin T, Siqueira CC, Bruno LS, Li X et al. :Salivary micelles:identification of complexes containing MG2, sIgA, lactoferrin, amylase, glycosylated proline-rich protein and lysozyme. Arch Oral Biol 49:337-343, 2004.
  pubmed

• 24) Teraguchi S, Shin K, Ogata T, Kingaku M, Kaino A et al. :Orally administered bovine lactoferrin inhibits bacterial translocation in mice fed bovinemilk. Appl Environ Microbiol 61:4131-4134, 1995.

• 25) Debbabi H, Dubarry M, Rautureau M, Tome D:Bovine lactoferrin induces both mucosal andsystemic immune response in mice. J Dairy Res65:283-293, 1998.

• 26) 高倉南津子, 若林裕之, 山内恒治, 田村吉隆, 山口英世・他:ラクトフェリンの感染防御効果とその作用メカニズム. ミルクサイエンス 53:187-191, 2004.

• 27) Yamauchic K, Hiruma M, Yamazaki N, Wakabayashi H, Kuwata H et al.: Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebocontrolled, double-blind study. Mycoses 43:197-202, 2000.

• 28) 山口英世:多機能タンパク質ラクトフェリンの抗真菌作用と医療への応用. 化学と生物 38:594-600, 2000.

• 29) Shimizu K, Matsuzawa H, Okada K, Tazume S Dosako S et al. :Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Arch Virol l41:1875-1889, 1996.

• 30) 久原徹哉, 山内恒治, 田村吉隆:ウシラクトフェリンの経口投与によるNK細胞活性の増加とその作用機序. ミルクサイエンス 53:262-264, 2004.

• 31) Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K et al.:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199, 2000.
  pubmed

• 32) Koshio S, Yokoyama S, Ishikawa M, Hayasawa H, Oshida K:Effect of lactoferrin on growth, survival and tolerance to stress of kuruma prawn Penaeus japonicus. Excerpta Med Int Congr Sr 1195:451-455, 2000.

• 33) 平田陸正:哺乳類がつくる抗菌蛋白質(CAP 18)のリポ多糖中和活性と生体防御. 蛋白質・核酸・酵素 46:575-581, 2001.

• 34) Kawai K, Nagahata H, Lee NY, Anri A, Shimazaki K:Effect of infusing lactoferrin hydrolysate into bovine mammary glands with subclinical mastitis. Vet Res Commun 27:539-548, 2003.
  pubmed

• 35) Kawai K, Shimazaki K, Higuchi H, Nagahata H:Antibactrial activity of bovine lactoferrin hydrolysate against mastitis pathogens and its effects on superoxide production of bovine neutrophils. Zoonoses Public Health 54:160-164, 2007.

• 36) Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase et al. :Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta l121:130-136, 1992.

• 37) Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S et al. :Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 182:97-105, 1993.

• 38) Jones EM, Smart A, Bloomberg G, Burgess L, Millar MR:Lactoferricin, a new antimicrobial peptide. J Appl Bacteriol 77:208-214, 1994.
  pubmed

• 39) Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M:Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73:472-479, 1992.

• 40) van der Kraan MI, Groenink J, Nazmi K Veerman EC, Bolscher JG et al:Lactoferrampin:a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25:177-183, 2004.
  pubmed

• 41) Yamauchi K, Tomita M, Giehl TJ, Ellison RT:Antibacterial activity of lactoferrin and a pepsinderived lactoferrin peptide fragment. Infect Immun 61:719-728, 1993.

• 42) Vogel HJ, Schibli DJ, Jing W, Lohmeier-Vogel EM, Epand RF et al. :Towards a structure-function analysis of bovine lactoferricin and related tryptophan-and arginine-containing peptides. Biochem Cell Biol 80:49-63, 2002.
  pubmed

• 43) Umeyama M, Kira A, Nishimura K, Naito A:Interactions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid-state NMR. Biochim Biophys Acta l758:1523-1528, 2006.

• 44) Hwang PM, Zhou N, Shan X, Arrowsmith CH, Vogel HJ:Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288-4298. 1998.
  pubmed

• 45) Shimazaki K, Tazume T, Uji K, Tanaka M, Kumura et al. :Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 81:2841-2849, 1998.
  pubmed

• 46) 正木春彦:バクテリオシンの多様性およびコリシンの構造と進化. 蛋白質・核酸・酵素 46:305-314, 2001.

• 47) Gado I, Erdei J, Laszlo VG, Paszti J, Czirok E et al. :Correlation between human lactoferrin binding and colicin susceptibility in Escherichia coli. Antimicrob Agents Chemother 35:2538-2543, 1991.
  pubmed

• 48) 園元謙二, 指原紀宏:乳酸菌のバクテリオシンの構造と作用機構. 蛋白質・核酸・酵素 46:323-332, 2001.

• 49) Branen JK, Davidson PM:Enhancement of nisin, lysozyme, and monolaurin antimicrobial activities by ethylenediaminetetraacetic acid and lactoferrin. Int J Food Microbiol 90:63-74, 2004.
  pubmed

• 50) Wu Z, Li X, de Leeuw E, Ericksen B, Lu W:Why is the Arg5-Glu13 salt bridge conserved in mammalian alpha-defensins? JBiol Chem 280:43039-43047, 2005.

• 51) de Leeuw E. Burks SR, Li X, Kao JP, Lu W:Structure-dependent functional properties of humandefensin 5, FEBS Lett 581:515-520, 2007
  pubmed

• 52) Superti F, Ammendolia MG, Valenti P, Seganti L:Antirotaviral activity of milk proteins:lactoferrin prevents rotavirus infection in the enterocyte-likecell line HT-29. Med Microbiol Immunol (Berl)186:83-91, 1997.
  pubmed

• 53) Hara K, Ikeda M, Saito S, Matsumoto S, Numata K et al:Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24:228-235, 2002.
  pubmed

• 54) 田中克明:ラクトフェリンによるC型肝炎治療の現状. ミルクサイエンス 53:362-364, 2004.

• 55) 佐藤れえ子, 小林沙織, 稲波 修, 佐藤 淳, 山田裕一・他:ネコ免疫不全症ウイルス(FIV)感染におけるウシラクトフェリンの抗炎症作用. ミルクサイエンス 53:296-298, 2004.

• 56) Hasegawa K, Motsuchi W, Tanaka S, Dosako S:Inhibition with lactoferrin of in vitro infection withhuman herpes virus. Jpn J Med Sci Biol 47:73-85, 1994.

• 57) Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J et al:In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol 145:1571-1582, 2000.
  pubmed

• 58) Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E et al. :Antiviral effects of plasma and milk proteins:lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172:380-388, 1995.
  pubmed

• 59) Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P et al. :Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 invitro infection. Antiviral Res 69:98-106, 2006.

• 60) Marchettic M, Superti F, Ammendolia MG, Rossi P, Valenti P et al.:Inhibition of poliovirus type 1 infection by iron-, manganese-and zinc-saturated lactoferrin. Med Microbiol Immunol(Berl) 187:199-204, 1999.

• 61) van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK:Antiviral activities of lactoferrin. Antiviral Res 52:225-239, 2001.
  pubmed

• 62) Tanaka K, Ikeda M, Nozaki A, Kato N Tsuda H et al:Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C:a pilot study. Jpn JCancer Res 90:367-371, 1999.

• 63) 阿部健一, 野崎昭人, 田村一志, 池田正徳, 仲 一仁・他:C型肝炎ウイルスエンベロープ蛋白質に結合するラクトフェリン由来ペプチドの同定とその感染防御活性. ミルクサイエンス 53:348-353, 2004.

• 64) Sato R, Inanami O, Tanaka Y, Takase M, Naito Y:Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus(FIV) -positive and FIV-negative cats. Am J Vet Res 57:1443-1446, 1996.

• 65) Kobayashi S, Sato R, Inanami O, Yamamori T Yamato O et al:Reduction of concanavalin A-induced expression of interferon-gamma by bovine lactoferrin in feline peripheral blood mononuclear cells. Vet Immunol Immunopathol 105:75-84, 2005.
  pubmed

• 66) 竹内 崇, 土屋友人, 林田健一郎, 原田悦守:ラクトフェリンによるモルヒネ耐性発現遅延効果とその作用機序. ミルクサイエンス 53:315-319, 2004.

• 67) Tanaka T, Omata Y, Saito A, Shimazaki K, Igarashi I, Suzuki N:Growth inhibitory effects of bovine lactoferrin to Toxoplasma gondii parasites in murine somatic cells. J Vet Med Sci 58:61-65, 1996.
  pubmed

• 68) Ikadai H, Tanaka T, Shibahara N, Tanaka H, Matsuu A et al. :Inhibitory effect of lactoferrin on in vitrogrowth of Babesia caballi. Am J Trop Med Hyg 73:710-712, 2005.

• 69) Eda S, Eda K, Prudhomme JG, Sherman IW:Inhibitory activity of human lactoferrin and its peptide on chondroitin sulfate A-, CD36-, and thrombospondin-mediated cytoadherence of plasmodium falciparum-infected erythrocytes. Blood 94:326-332, 1999.
  pubmed

• 70) Liepke C, Adermann K, Raida M, Magert HJ, Forssmann WG, Zucht HD:Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem 269:712-718, 2002.
  pubmed

• 71) Kim WS, Ohashi M, Tanaka T, Kumura H, Kim GY et al. :Growth-promoting effects of lactoferrin on L. acidophilus and Bifidobacterium spp. BioMetals 17:279-283, 2004.

• 72) Saito H, Miyaka H, Ishibashi N, Tamura Y, Hayasawa H et al. :Effect of iron-ree and metal-bound forms of lactoferrin on the growth of Bifidobacteria, E. coli and S. aureus. Biosci Microfiora 15:1-7, 1996.

• 74) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. ミルクサイエンス 53:365-368:2004.

シンポジウム"ラクトフェリンと健康"

P.25 掲載の参考文献

• 1) Ohashi A, Murata E, Yamamoto K et al. :New functions of lactoferrin and β-casein in mammalian milk as cysteine protease inhibitors. BBRC 306:98-103, 2003.

• 2) Sano E, Miyauchi R, Takakura N et al. :Cysteine protease inhibitors in various milk preparations and its importance as a food. Food Research International 38:427-433, 2005.

• 3) Kakegawa H, Nikawa T, Tagami K et al. :Participation of cathepsin L on bone resorption. FEBS-Lett 321:247-250, 1993.

• 4) Katunuma N:Molecular mechanisms of bone collagen degradation in bone resorption. Journal of Bone and Mineral Metabolism 15:1-8, 1997.

• 5) Katunuma N:Mechanism and regulation of bone resorption by osteoclasts. Current Topics in Cellular Regulation 35:179-192, 1997.
  pubmed

• 6) Katunuma N, Tsuge H, Nukatsuka M et al. :Structure-based design of specific cathepsin inhibitors and their apPlication to protection of bone metastasis of cancer cells. Archives of Biochemistry and Biophysics (ABB) Mini-review 397:305-311s 2002.

• 7) Le QT, Ohashi A, Hirose S:Reverse zymography using fluorogenic substrates for protease inhibitor detection. Electrophoresis 26:1038-1045, 20058.

• 8) Nagasawa T, Kiyosawa I, Kuwahara K:Amounts of lactoferrin in human colostrum and milk. J Dairy Sci55:1651-1659, 1972.

• 9) Hirai Y, Kawakata N, Satoh K et al. :Concentrations of lactoferrin and iron in human milk at different stages of lactation. J Nutr Sci Vitaminol (Tokyo) 36:531-544, 1990.
  pubmed

• 10) Suzuki T, Nonaka M, Kiyosawa I et al:Lactoferrin contents in bovine colostrum and milk. J Jpn Soc Food Nutri 30:317-322, 1977.

• 11) Lorget F. Clough J, Oliveira M et al. :Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 296:261-266, 2002. 12

• 12) Takeshita S, Kaji K, Kudo A et al:Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being ableto differentiate into mature osteoclasts. J Bone Miner Res 15:1477-1488, 2000.

• 13) Miyamoto K, Hase K, Taketani Y, Minami H, Oka Tet al. :Diabetes and glucose transporter gene expression in rat small intestine. Biochem BiophysRes Commun 181:111C-1117, 1991.

• 14) Kashimura J, Nagai Y:Inhibitory effect of palatinose on glucose absorption in everted rat gut. J Nutr Sci Vitaminol 53:87-89, 2007.

• 15) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89:263-270, 2004.
  pubmed

• 16) Kitagawa H, Yoshizawa Y, Yokoyama T et al. :Persorption of bovine lactoferrin from the intestinallumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs J Vet Med Sci 65:567-572, 2003.
  pubmed

P.30 掲載の参考文献

• 1) Tanaka K et al. :Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C:a pilot study. Jpn J Cancer Res 90:367-371, 1999.
  pubmed

• 2) Iwasa M et al. :Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype lb. Am J Gastroentero1 97:766-767, 2002.

• 3) Ishii K et al:Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12months. Hepatol Res 25:226-233, 2003.

• 4) Ueno H et al, :Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C, Cancer Sci 97:1105-1110, 2006,
  pubmed

• 5) Hirashima N et al, :Arandomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype lb and high viral load, Hepatol Res 29:9-12, 2004.

• 6) Ishibashi Y et al. :Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 32:218-223, 2005.
  pubmed

• 7) Kaito M et al.:Effect of lactoferrin in patients with chronic hepatitis C:combination therapy with interferon and ribavirin. J Gastroen Hepatol (inpress).

• 8) Gutteridge JM et al. :Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J l99:259-261, 1981.

• 9) Wakabayashi H et al. :Inhibition of iron/ascorbate-induced lipid peroxidation by an N-terminal peptide of bovine lactoferrin and its acylated derivatives. Biosci Biotechnol Biochem 63:955-957, 1999.

• 10) Togawa J et al. :Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 283:187-195, 2002.

• 11) Shin K et al. :Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J Med Microbiol 54:717-723, 2005.
  pubmed

• 12) Konishi M et al. :Increased lipid peroxidation in patients with nonalcoholic fatty liver disease, chronic hepatitis C and hepatocellular carcinoma as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 21:1821-1825, 2006.
  pubmed

• 13) Kaito M et al. :lron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C. J Gastroenterol 41:921-922, 2006.

• 14) 岩田加壽子・他:食事療法-鉄制限食療法. 肝胆膵 52:927-932, 2006.
  Medical*Online

P.35 掲載の参考文献

• 1) Otsuki K, Yoda A, Hirose K, Shimizu Y, Saito H et al. :Salivary lactoferrin in neonates with chorioamnionitis. Showa Univ J Med Sci 9(1):39-44, 1997.

• 2) Otsuki K, Yoda A, Toma Y, Shimizu Y, Saito H et al:Lactoferrin and interleukin-6 interaction in amniotic infection. Adv Exp Med Biol 443:267-271, 1998.
  pubmed

• 3) Sawada M, Otsuki K, Yakuwa K, Mitsukawa K, Nagatsuka M et al. :Cervical inflammatory cytokines and other markers in cervical mucus of pregnant women with lower genital tract infections. Int J Gynecol Obstet 92:117-121, 2006.

• 4) 大槻克文, 斎藤 裕, 矢内原巧:サンドイッチELISA法を用いた新生児唾液中ラクトフェリン濃度の測定. 日本産科婦人科栄養・代謝研究会誌 2(1):67, 1996.

• 5) 依田 暁, 大槻克文, 藤間芳郎, 清水幸子, 斎藤 裕・他:絨毛膜羊膜炎における羊水中Lactoferrin測定の臨床的意義. 日本産科婦人科栄養・代謝研究会誌 6(1):57-58, 1997.

• 6) Otsuki K, Yoda A, Mitsuhashi Y, Toma Y, Shimizu Y et al. :Amniotic fluid lactoferrin in intrauterine infection. Placenta 20 (2-3):175-179, 1999.

• 7) Otsuki K, Yoda Y, Mitsuhashi Y, Shimizu Y, Saito H et al. :Isolation and detection of human lactoferrin binding protein in human amniotic membrane. Lactoferrin:Structure, Function and Applications 343-346, 2000.

• 8) 齋藤 裕, 大槻克文, 依田 暁, 矢内原巧:子宮内感染と早産-子宮内感染におけるラクトフェリンの感染防御機構について. 周産期学シンポジウム16号. 111-114, 1998.

• 9) 依田 暁, 大槻克文, 三橋裕一, 清水幸子, 齋藤 裕・他:絨毛膜羊膜炎をきたした早産症例における羊水中ラクトフェリンとIL-6の動態. 日本新生児学会雑誌 34(3):506-510, 1998.

• 10) Saito H, Otsuki K, Mitsuhashi Y, Yoda Y, Yanaihara Aet al. :Role of lactoferrin in the prevention of preterm delivery. Lactoferrin:Structure, Function and Applications 347-352, 2000.

• 11) Mitsuhashi Y, Otsuki K, Yoda Y, Shimizu Y, Saito H et al. :Effect of lactoferrin on lipopolysaccharide (LPS) induced preterm delivery in mice, Acta Obstet Gynecol Scand 79:355-358, 2000.

• 12) Sherman MP, Otsuki K, Lonnerdal BL:Preventing Escherichia coli growth on cervical epithelium. Pediatr Res 49:232A, 2001.

• 13) Otsuki K, Lonnerdal BL, Sherman MP:Lactoferrin:bacterial opsonin for macrophages?. Biochemistry and Cell Biology 80:158, 2002.

• 14) Otsuki K, Lonnerdal BL, Sherman MP:Bacterial growth on human cervical epithelia:A new assay for testing killing by lactoferrin. Biochemistry and Cell Biology 80:165, 2002.

• 15) Sasaki Y, Otsuki K, Hasegawa A, Sawada M, Chiba Het al. :Preventive effect of recombinant humanLactoferrin on lipopolysaccharide-induced pretermdelivery in mice. Acta Obstet Gynecol Scand 83:1035-1038, 2004.

• 16) Otsuki K, Sasaki Y, Hasegawa A, Sawada M Mitsukawa K et al. :Lactoferrin concentrations incervical mucus of pregnant women with and without infection. Am J Obstet Gynecol 191:S75, 2004.

• 17) Ilasegawa A, Otsuki K, Sasaki Y, Sawada M, Mitsukawa K et al. :Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model. Am J Obstet Gynecol 192:1038-1043, 2005.

• 18) Otsuki K, Hasegawa A, Sasaki Y, Sawada M Yakuwa K et al:Potential of lactoferrin in the prevention of preterm delivery. Taiwanese J ObstetGynecol 44:123-127, 2005.

• 19) Otsuki K, Yakuwa K, Sawada M, Hasegawa A, Sasaki Y et al. :Recombinant human lactoferrin hasa preventive effects on lipopolysaccharide-inducedpreterm delivery and production of inflammatorycytokines. J Perinat Med 33:320-323, 2005.

• 20) 大槻克文, 長谷川明俊, 澤田真紀, 満川香織, 千葉 博・他:ラクトフェリンによる体内での炎症性サイトカイン産生抑制を解した早産予防の試み. Milk Science 53(4):304-305, 2004.

• 21) 長谷川明俊, 大槻克文, 佐々木 康, 澤田真紀, 満川 香織・他:ラビット早産モデルにおけるlactoferrinの早産防止効果. Milk Science 53(4):306-308, 2004.

• 22) 長谷川明俊, 大槻克文, 佐々木 康, 澤田真紀, 千葉 博・他:マウス早産モデルにおけるRecombinant human lactoferrinの早産防止効果. 日本周産期・新生児医学会雑誌 40(1):35-39, 2004.
  Medical*Online

• 23) 大槻克文:超早産の病態, 予後及び予防への展望-Lactoferrinによる超早産予防の可能性. 日本周産期・新生児医学会雑誌 40(4):759-762, 2004.

• 24) Romero R, Yoon BH, Mazor M et al. :The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. Am J Obstet Gynecol 169:805-816, 1993.
  pubmed

• 25) Yoon BH, Park CW, Chaiworapongsa T:Intrauterine infection and the development of cerebral palsy. Br J Obstet Gynecol 110 Suppl:20:124-127, 2003.

• 26) Dudley DJ:Pre-term labor:an intra-uterine inflammatory response syndrome? JReprod Immunol 36:93-109, 1997.
  pubmed

• 27) Kaga N, Katsuki Y, Obata M et al:Repeated administration of low-dose lipopolysaccharide induces preterm delivery in mice. A model for human preterm parturition and for assessment of the therapeutic ability of drugs against preterm delivery. Am J Obstet Gynecol 174:754-759, 1996.

• 28) Kaga N, Katsuki Y, Futamura Y et al. :Role of urinary trypsin inhibitor in the maintenance of pregnancy in mice. Obstet Gynecol 88:872-882, 1996.
  pubmed

• 29) Kaga N, Katsuki Y, Kajikawa S et aL. :Preventive effect of ritodrine hydrochloride and/or urinary trypsin inhibitor against lipopolysaccharide-induced preterm delivery in mice. Acta Obstet Gynecol Scand 76:811-816, 1997.
  pubmed

• 30) Machnicki M, Zimecki M, Zagulski T:Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin-6 in vivo. Int J Exp Pathol 74:433-438, 1993.
  pubmed

• 31) Zhang GH, Mann DM, Tsai CM:Neutralization of endotoxin in vivo and in vivo by a human lactoferrin-derived peptide. Infect Immun 67:1353-1358, 1999.
  pubmed

• 32) Kanayama N, el Maradny E et al. :Urinary trypsin inhibitor suppresses premature cervical ripening. Eur J Obstet Gynecol Reprod Biol 60:181-186, 1995.
  pubmed

P.41 掲載の参考文献

• 1) Harada E, Itoh Y, Sitizyo K, Takeuchi T, Araki Y et al:Characteristic transport of lactoferrin from the intestinal lumen into the bile via the blood in piglets. Comp Biochem Physiol 124A:321-327, 1999.

• 2) Harada E, Sugiyama A, Takeuchi T, Sitizyo K, Syuto Bet al:Characteristic transfer of colostral components into cerebrospinal fluid via serum in neonatal pigs. Biol Neonate 76:33-43, 1999.

• 3) Harada E, Araki Y, Furumura E, Takeuchi T, Sitizyo K et al. :Characteristic transfer of colostrum derived biologically active substances into cerebrospinal fluid via blood in natural suckling neonatal pigs. J Vet Med A 49:358-364, 2002.

• 4) Talukder MJR, Takeuchi T and Harada E:Characteristic transport of colostral macromolecules into the cerebrospinal fluid via plasma in newborn calves. J Dairy Sci 85:514-524, 2002.

• 5) 原田悦守:新生仔腸管における高分子物質の取込みとgut closure. 医学のあゆみ 198:959-964, 2001.
  Medical*Online

• 6) Talukder MJR, Takeuchi T, Harada E:Receptormediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci 65:957-964, 2003.

• 7) Talukder MJR, Takeuchi T, Harada E:Characteristics of lactoferrin receptor in bovineintestine:higher binding activity to the epithelium overlying Peyer's patches. J Vet Med A 50:123-131, 2003.

• 8) Kitagawa H, Yoshizawa Y, Yokoyama T, TakeuchiT, Talukder MJR et al:Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lym phatics in growing pigs. J Vet Med Sci 65:567-572, 2003.

• 9) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89 (3):263-270, 2004.
  pubmed

• 10) 原田悦守, 竹内崇, 北川 浩, 橋本善春:ラクトフェリンの体内移行動態:特にリンパ系を介した腸管からの取り込みについて. ミルクサイエンス 53:328-333, 2004.

• 11) Takeuchi T, Hayashida K, Inagaki H, Kuwahara M, Tsubone H et al:Opioid mediated suppressive effect of milk-derived lactoferrin on distress inducedby maternal separation in the rat pups. Brain Res 979:216-224, 2003.

• 12) Kamemori N, Takeuchi T, Hayashida K, Harada E:Suppressive effects of milk-derived lactoferrin on the psychological stress in adult rats. Brain Res 1029:34-40, 2004.
  pubmed

• 13) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Novel central function of milk-derived lactoferrin on antinociception mediated by μ-opioid receptor in the rat spinal cord. Brain Res 965:239-245, 2003.

• 14) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. Am J Physiol 285:R306-R312, 2003.

• 15) Tsuchiya T, Takeuchi T, Harada E:Milk-derived lactoferrin possibly block tolerance to morphine analgesia via nNOS activation in mice. Brain Res 1068:102-108, 2006.
  pubmed

• 16) 原田悦守:ミルク由来ラクトフェリンの体内移行動態とその新規作用. -抗ストレス, 鎮痛, 抗炎症作用-. 慢性疼痛 23:9-23, 2004.

• 17) 原田悦守:ミルクに含まれるラクトフェリンの脳内移行とその新規作用. ペインクリニック 26:359-368, 2004.

• 18) Hayashida K, Takeuchi T, Harada E:Lactoferrinenhances peripheral opioid-mediated antinociceptionvia nitric oxide in rats. Eur J Pharmacol 484:175-181, 2004.
  pubmed

• 19) Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K, Harada E:Oral administration oflactoferrin inhibits inflammation and nociception inrat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.

• 20) Hayashida K, Takeuchi T, Ozaki T, Shimizu H, Ando K et al.:Bovine lactoferrin has a nitric oxidedependent hypotensive effect in rats. Am J Physiol 286:R359-R365, 2004.

• 21) Takeuchi T, Shimizu H, Ando K, Harada E:Bovine lactoferrin reduces plasma tri-acylglycerol and NEFA accompanied by decreased hepaticcholesterol and tria-cylglycerol contents in rodents. Br J Nutr 91:533-538, 2004.

• 22) Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H et al. :Enteric-formulated lactoferrin was more effectively transported into blood ciculation from gastrointestinal tract in adult rats. Exp Physiol 91:1033-1040,2006.

P.49 掲載の参考文献

• 1) Levay PF, Viljoen M:Lactoferrin:a general review. Haematologica 80(3):252-267, 1995.
  pubmed

• 2) Mattsby-Baltzer I, Roseanu A, Motas C, Elverforts J, Engberg I et al. :Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 responsein human monocytic cells. Pediatr Res 40(2):257-262, 1996.

• 3) Chierici R, Sawatzki G, Tamisari L, Volpato S, Vigi V:Supplementation of an adapted formula withbovine lactoferrin. 2. Effects on serum iron, ferritin and zinc levels. Acta Paediatr 81(6-7):475-479 1992.

• 4) Ikeda M, Sugiyama K, Tanaka T, Tanaka T, Tanaka K et al. :Lactoferrin markedly inhibits hepatitis Cvirus infection in cultured human hepatocytes. Biochem. Biophys. Res Commun 245(2):549-553, 1998.

• 5) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28(3):893-898, 1980.
  pubmed

• 6) Yamaguchi K, Wakabayashi H, Hashimoto S, Teraguchi S, Hayasawa H et al. :Effects of orally administered bovine lactoferrin on the immunesystem of healthy volunteers. Adv Exp Med Biol 443:261-265, 1998.

• 7) Ambruso DR, Johnston RB Jr:Lactoferrin enhanceshydroxyl radical production by human neutrophils, neutrophil particulate fractions, and an enzymaticgenerating system. J Clin Invest 67(2):352-360, 1981

• 8) Sekine K, Watanabe E, Nakamura J, Takasuka N Kim DJ et al. :Inhibition of azoxymethane-initiatedcolon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 88( 6):523-526, 1997.
  pubmed

• 9) Kanemori N, Takeuchi T, Hayashida K, Harada E:Suppressive effects of milk-derived lactoferrin on psychological stress in adult rats. Brain Res 1029(1):34-40, 2004.

• 10) Hayashida K, Takeuchi T, Shimuzu H, Ando K, Harada E:Novel function of bovine milk-derivedl actoferrin on antinociception mediated by mu-opioid receptor in the rat spinal cord. Brain Res 965 (1-2):239-245, 2003.

• 11) Takeuchi T, Shimizu H, Ando K, Harada E:Bovinvine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepaticcholesterol and triacylglycerol contents in rodents. BrJNutr 91(4):533-538, 2004.

• 12) Lyons TE, Miller MS, Serena T, Sheehan P, Lavery aL:Talactoferrin Alfa, a ricombinant humanlactoferrin promotes heeling of diabetic neuropathiculcers:aphase 1/2 clinical trials. Am J Surg 193(1):49-54, 2007.

• 13) Wang Y, Raghunadharao D, Raman G, Doval D, Advani S et al:Adding oral talactoferrin to firstline NSCLC chemotherapy safely enhanced efficacy in a randomized trial. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)24 (18S):7095, 2006.

• 14) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89(3):263-270, 2004.
  pubmed

• 15) Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H et al. :Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91(6):1033-1040, 2006.
  pubmed

• 16) Wang YS, Youngster S, Grace M, Bausch J, Bordens R et al:Structural and biological characterization ofpegylated recombinant interferon alpha-2b and ittherapeutic implications. Adv Drug Deliv Rev 54(4):547-570, 2002.
  pubmed

• 17) Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ et al. :Rational design of a potent, long. lastingform of interferon:a40 kDa branched polyethyleneglycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12(2):195-202, 2001.

• 18) Kodera Y, Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem BiophysRes Commun 184(1):144-148, 1992.
  pubmed

• 19) Shimazaki K, Hosokawa T:A tentative method for rapid preparation of ion-saturated lactoferrin by affinity chromatography, Animal Sci Technol(Chikusan Gakkai-ho) 62(4):354-356, 1991.

P.55 掲載の参考文献

• 1) Wakabayashi H, Yamauchi K, Takase M:Lactoferrin research, technology and applications. Int Dairy J 16:1241-1251, 2006.

• 2) 津田洋幸, 深町勝巳, 徐 結苟, 飯郷正明, 関根一則・他:多機能性蛋白質ウシラクトフェリンによるがん予防の試み. FFI Journal 211:740-747, 2006.

• 3) Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y:Protection against infections by oral lactoferrin:evaluation in animal models. Biometals 17:231-234, 2004.
  pubmed

• 4) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89:263-270, 2004.
  pubmed

• 5) Takeuchi T, Jyonotsuka T. Kamemori N, Kawano G, Shimizu H et al. :Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91:1033-1040, 2006.
  pubmed

• 6) Wakabayashi H, Kuwata H, Yamauchi K, Teraguchi S, Tamura Y:No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci. Biotechnol. Biochem 68:853-860, 2004.
  pubmed

• 7) 若林裕之, 桑田英文, 高倉南津子, 山内恒治, 寺口 進・他:経口摂取したラクトフェリンとその機能性消化断片の血液移行性の検討 . Milk Science 53:339-342, 2004.

• 8) Regoeczi E, Chindemi PA, Debanne MT, Prieels JP:Lactoferrin catabolism in the rat liver. Am J Physiol 248:G8-G14, 1985.
  pubmed

• 9) Takakura N, Wakabayashi H, Yamauchi K, Takase M:Influence of orally administered lactoferrin on IFN-y and IL-10 production by intestinal intra epithelial lymphocytes and mesenteric lymph-node cells. Biochem Cell Biol 84:363-368, 2006.

• 10) Wakabayashi H, Takakura N, Yamauchi K, Tamura Y:Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 13:239-245, 2006.
  pubmed

• 11) Wang WP, Iigo M, Sato J, Sekine K, Adachi I et al. :Activation of intestinal mucosil immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 91:1022-1027, 2000.

• 12) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. Milk Science 53:365-368, 2004.

P.59 掲載の参考文献

• 1) 館野之男:放射線と健康. 岩波新書, 2001.

• 2) Draganic IG, Draganic ZD, Adolff JP, 松浦辰雄・他 訳:放射線と放射能-宇宙・地球環境におけるその存在と働き-. 学会出版センター, 1996.

• 3) Sigdestad CP, Grdina DJ, Connor AM, Hanson WR:A comparison of radioprotection from three neutron sources and 60 Co by WR-2721 and WR-151327. Radiat Res 106:224-233, 1986.

• 4) 西村義一・他:日本放射線影響学会第48回大会講演要旨集. 広島市, 2005.

• 5) 井上正康・編著:活性酸素と医食同源. 共立出版, 1999.

• 6) 井上正康・編著:活性酸素と運動. 共立出版, 1999.

一般演題およびポスターセッション

P.67 掲載の参考文献

• 1) Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y:Protection against infections by oral lactoferrin:evaluation in animal models. Biometals 17(3):231-234, 2004.
  pubmed

• 2) Yamauchi K, Wakabayashi H, Shin K, Takase M:Bovine lactoferrin:benefits and mechanism of action against infections. Biochem Cell Biol 84(3):291-296, 2006.
  pubmed

• 3) 鯉川なつえ, 仲村 明, 長岡 功, 山日正弘, 澤木啓祐・他:女子長距離ランナーの潜在的な運動性貧血に対するLF摂取の有用性. 第16回日本臨床スポーツ医学会学術集会講演要旨, 東京, 2005.

P.72 掲載の参考文献

• 1) 厚生労働省医政局歯科保健課:平成17年歯周疾患実態調査. 口腔保健協会, 2005.

• 2) Beck JD, Offenbacher S:The association between periodontal diseases and cardiovascular diseases:a state-of. the-science review. Ann Periodontol 6:9-15, 2001.
  pubmed

• 3) Nishimura F, Kono T, Fujimoto C, Iwamoto Y, Murayama Y:Negative effects of chronic inflammatory periodontal disease on diabetes mellitus. J Int Acad Periodontol 2:4955, 2000.

• 4) Offenbacher S, Katz V, Fertik G, Collins J, Boyd D et al. :Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 67:1103-1113, 1996.

• 5) 財団法人ライオン歯科衛生研究所・編:歯周病と全身の健康を考える. 医歯薬出版, 2004, p271-280.

• 6) Mahanonda R, Pichyangkul S:Toll-like receptors and their role in periodontal health and disease. Periodontology 2000 43:41-55, 2007.
  pubmed

• 7) Suzuki YA, Lopez V, Lonnerdal B:Mammalian lactoferrin receptors:structure and function. Cell Mol Life Sci 62:2560-2575, 2005.
  pubmed

• 8) Takayama Y, Takezawa T:Lactoferrin promotes collagen gel contractile activity of fibroblasts mediated by lipoprotein receptors, Biochem Cell Biol 84:268-274, 2006.
  pubmed

• 9) Grey A, Banovic T, Zhu Q, atson M, Callon K et al. :The low-density lipoprotein receptor-related protein l is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268-2278, 2004.

• 10) Strickland DK, Gonias SL, Argraves WS:Diverse roles for the LDL receptor family. Trends Endocrinol Metab 13:66-74, 2002.
  pubmed

• 11) Paquette DW, Waters GS. Stefanidou VL, Lawrence HP, Friden PM et al. :Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J Clin Periodontol 24:216-222, 1997.
  pubmed

P.82 掲載の参考文献

• 1) Siebert PD, Huang BC:Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci USA 94:2198-2203, 1997.
  pubmed

• 2) Mariller C, Benaissa M, Hardiville S, Breton M, Pradelle G et al. :Human delta-lactoferrin is a transcription factor that enhances Skpl (S-phase kinase-associated protein) gene expression. FEBS Journal, Online Early Articles, 2007.

• 3) Breton M, Mariller C, Benaissa M, Caillaux K, Browaeys E et al. :Expression of delta-lactoferrin induces cell cycle arrest. Biometals 17:325-329, 2004.
  pubmed

• 4) Notredame C, Higgins D, Heringa J:T-coffee:a novel method for fast and accurate multiple sequence alignments. Journal of Molecular Biology 302:205-217, 2000.

• 5) Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ et al. :Multiple sequence alignment with the Clustal series of programs, Nucleic Acids Res 31:3497-3500, 2003.
  pubmed

• 6) Guex N, Peitsch MC:SWISS-MODEL and the Swiss-PdbViewer:an environment for comparative protein modeling. Electrophoresis 18:2714-2723 1997.
  pubmed

• 7) Hunter HN, Demcoe AR, Jenssen H, Gutteberg TJ, Vogel HJ:Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrobial Agents and Chemotherapy 49:3387-3395, 2005.

P.87 掲載の参考文献

• 1) Takayama Y, Mizumachi K:Effects of lactoferrin on collagen gel contractile activity and myosin light chain phosphorylation in human fibroblasts. FEBS lett 508:111-116, 2001.
  pubmed

• 2) Takayama Y, Takahashi H, Mizumachi K, Takezawa T:Low-density Iipoprotein receptor-related protein (LRP) is required for lactoferrin-enhanced collagen gel contractile activity in human fibroblasts. J Biol Chem 278:22112-22118, 2003.

• 3) Grey A, Banovic T, Zhu Q, Watson M, Callon K et al:The low-density lipoprotein receptor-related protein l is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268-2278, 2004.

• 4) Cornish J, Palmano K, Callon KE, Watson M, Lin JM et al. :Lactoferrin and bone:structure-activity relationships. Biochem Cell Biol 84:297-302, 2006.
  pubmed

• 5) Andreadis ST, Geer DJ:Biomimetic apProaches to protein and gene delivery for tissue regeneration. Trends Biotechnol 24:331-337, 2006.
  pubmed

• 6) Babensee JE, Mclntire LV, Mikos AG:Growth factor delivery for tissue engineering. Pharm Res 17:497-504, 2000.

• 7) Groeneveld EHJ. Burger EH:Bone morphogenic proteins in human bone regeneration. Eur J Endocrinol 142:9-21, 2000.

• 8) 田畑泰彦:ドラッグデリバリーシステムとティッシュエンジニアリング. ティッシュエンジニアリング 2005. (田畑泰彦, 岡野光夫・編), 日本医学館, 東京, 2005, p92-99.

• 9) Takezawa T, Ozaki K, Nitani A, Takabayashi C, Shimo-Oka T:Collagen vitrigel:a novel scaffold that can facilitate a three-dimensional culture for reconstructing organoids. Cell Transplant 13:463-473, 2004.
  pubmed

• 10) 竹澤俊明, 二谷 綾:新しい三次元培養担体-コラーゲンゲル薄膜. 化学と生物 42:713-716, 2004.

• 11) Takezawa T, Nitani A, Shimo-Oka T, Takayama Y:Protein-permeable scaffold of a collagen vitrigel membrane useful for reconstructing crosstalk models between two different cells. Cells Tissues Organs, (印刷中) .

• 12) Takagishi Y, Kawakami T, Hara Y, Shinkai M, Takezawa T et al. :Bone-like tissue formation by three-dimensional culture of MG630steosarcoma cells in gelatin hydrogels using calcium-enriched medium. Tissue Eng 12:927-937, 2006.
  pubmed

P.92 掲載の参考文献

• 1) Soria JC, Kim ES, Fayette J, Lantuejoul S, Deutsch E et al. :Chemoprevention of lung cancer. Lancet Oncol 4:659-669, 2003.
  pubmed

• 2) Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ et al. :Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 88:523-526, 1997.
  pubmed

• 3) Fujita K, Ohnishi T, Sekine K, Iigo M, Tsuda H:Down-regulation of 2-amino-3, 8-dimethylimidazo [4, 5-flquinoxaline(MeIQx) -induced CYPIA2 expression is associated with bovine lactoferrin inhibition of MelQx-induced liver and colon carcinogenesis in rats. Jpn J Cancer Res 93:616-625, 2002.

• 4) Tanaka T, Kawabata K, Kohno H, Honjo S, Murakami M et al:Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn J Cancer Res 91:25-33, 2000.
  pubmed

• 5) Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M et al:Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl) -1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett 246:41-46, 2007.

• 6) Ushida Y, Sekine K, Kuhara T, Takasuka N, ligo M et al. :Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res 90:262-267, 1999.

• 7) Masuda C, Wanibuchi H, Sekine K, Yano Y, Otani S et al. :Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis. Jpn J Cancer Res 91:582-588, 2000.

• 8) Takeuchi H, Saoo K, Yokohira M, Ikeda M, Maeta H et al. :Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitr-samino) -1-(3-pyridy)-1-butanone in female A/J mice. Cancer Res 63:7 581-7583, 2003.

• 9) Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K et al. :Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice. Cancer Lett 234:232-238, 2006.

• 10) Shimizu H:Development of an enteric-coated lactoferrin tablet and its application. Biometals 17:343-347, 2004.
  pubmed

• 11) Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H et al. :Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91:1033-1040, 2006.
  pubmed

• 12) Imaida K, Sato H, Okamiya H, Takahashi M, Hayashi Y:Enhancing effect of high fat diet on 4-nitroquinoline 1-oxide-induced pulmonary tumorigenesis in ICR male mice. Jpn J Cancer Res 80:499-502, 1989.
  pubmed

• 13) Abrink M, Larsson E, Gobl A, Hellman L:Expression of lactoferrin in the kidney:implications for innate immunity and iron metabolism. Kidney Int 57:2004-2010, 2000.
  pubmed

P.104 掲載の参考文献

• 1) 富田 守:乳業への膜利用. MRC News 19:247106-247108, 1997.

• 2) 田村吉隆, 齋藤仁志:膜技術を活用したラクトフェリンの製造. 膜 30(4):192-197, 2005.

• 3) 田村吉隆:乳中の機能成分の探索と製品への応用-ラクトフェリンを中心として-. 化学工学 68:469-471, 2004.

• 4) Chiu CK, Etzel MR:Fractionation of Lacto-peroxidase and Lactoferrin from Bovine Whey Using a Cation Exchange Membrane. J Food Sci 62(5):996-1000, 1997.

• 5) Hurly WL, Grieve RCJ, Magura CE, Hegarty HM, Zou S:Electrophoretic comparisons of lactoferrin from bovine mammary secretions, milk neutrophils, and human milk. J Dairy Sci 76:377-387, 1993.

• 6) Walsh MK, Nam SH:Affinity Enrichment of Bovine Lactoferrin in Whey. Prep Biotechnol 31(3):229-240, 2001.
  pubmed

• 7) Riechel P, Weiss T, Weiss M, Ulber R, Buchholz H ct al. :Determination of the minor whey protein bovine lactoferrin in cheese whey concentrates with capillary electrophoresis. Journal of Chromatography A 817:187-193, 1998.

• 8) Inoue H, Yamasaki M, Lakshmi DS, Kojo T, Yamagishi S:Effects of supersonic treatment on lactoferrin separation from whey using reversed micellar system. Environ Protection Eng 31(3-4):5-12, 2005.

• 9) HuZ, Gulari E:Protein extraction using the sodium bis (2-ethylhexyl) phosphate (NaDEHP) reverse micellar system. Biotechnol Bioeng 50(2):203-206, 1996.

• 10) Goto M, Ono T, Nakashio F, Hatton A:Design of surfactants suitable for protein extraction by reversed micelles. Biotechnol Bioeng 54(1):26-32, 1997.

P.110 掲載の参考文献

• 1) Kumar P, Khan J A, Yadav S, Singh TP:Crystal structure of equine apolactoferrin at 303 K providing further evidence of closed conformation of N and C lobes. Acta Crystallogr D 58(2):225-232, 2002.

• 2) Fine DH, Furgang D:Lactoferrin iron levels affect attachment of Actinobacillus actinomycetemcomitans to buccal epithelial cells. J Periodontol 73(6):616-623, 2002.
  pubmed

• 3) Superti F, Ammendolia MG, Valenti P, Seganti L:Antirotaviral activity of milk proteins:lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immun 186(2-3):83-91, 1997.

• 4) Leon-Sicairos N, Lopez-Soto F, Reyes-Lopez M, Godinez-Vargas D, Ordaz-Pichardo C et al. :Amoebicidal activity of milk, apo-lactoferiin, sIgA and lysozyme. Clin Med Res 4(2):106-113:2006.

• 5) Norrby K:Human apo-lactoferrin enhances angiogenesisi mediated by vascular endothelial growth factor A in vivo. J Vasc Res 41 (4):293-304, 2004.
  pubmed

• 6) Seno M, Yamabe T:On the electrolytic rectification effect in ion exchange memebrane. Bull Chem Soc Jpn 37:668-671, 1964.

• 7) Lovrecek B, Kunst B:Rectifying mechanism of 'pressed sandwich' type membrane junction. Electrochim Acta 12:687-692, 1972.

• 8) Holdik H, Alcaraz A, Ramirez P, Mafe S:Electric field enhanced water dissociation at the bipolar membrane from ac impedance spectra measurement. J Electroanal Chem 442:13-18, 1998.

• 9) Simons R:Preparation of a high performance bipolar membrane. J Membr Sci 78:13-23, 1993.

P.116 掲載の参考文献

• 1) Yamauchi K et al. :Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265, 1998.
  pubmed

• 2) Ambruso DR, Johnston RB Jr:Lactoferrin enhances hydroxyl radical production by human neutrophils, neutrophil particulate fractions, and an enzymatic generating system. J Clin Invest 67:352-360, 1981.

• 3) Iigo M et al:Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis 17:35-40, 1999.
  pubmed

• 4) Bailon P et al. :Rational design of a potent, long-lasting form of interferon:a 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjugate Chem 12:195-202, 2001.

• 5) Veronese FM, Pasut G:PEGylation, successful approach to drug delivery. Drug Discovery Today 451-1458, 2005.

• 6) Kodera Y, Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with acomb-shaped copolymer of polyethylene glycolderivative and maleic anhydride. Biochemical andBiophysical Research Communications 184:144-148, 1992.

• 7) Kaneda Y et al. :Bioconjugation of tumor necrosisfactor-awith the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency. Biochemical and Biophysical Research Communications 239:160-165, 1997.

• 8) Shimazaki K et al. :Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 81:2841-2849, 1998.
  pubmed

• 9) Snyder LR et al. :高速液体クロマトグラフィーの実際. (高橋 昭, 荒木 峻・訳), 東京化学同人, 2003, p1-249.

P.122 掲載の参考文献

• 1) Schanbacher FL, Talhouk RS, Murray FA, Gherman II, Willett LB:Milk-borne bioactive peptides. Int Dairy J 8:393-403, 1998.

• 2) Baintner K, Toth I:Failure to demonstrate intestinal absorption of RNA in the newborn pig:preliminary communication. Acta Vet Hungarica 34:239-241, 1986.

• 3) Gonnella PA, Siminoski K, Murphy RA, Neutra MR:Transepithelial transport of epidermal growth ctor by absorptive cells of suckling rat ileum. J Clin Invest 80:22-32, 1987.

• 4) Harada E, Sugiyama A, Takeuchi T, Sitizyo K, Syuto B et al:Characteristic transfer of colostral components into cerebrospinal fluid via serum in neonatal pigs. Biol Neonate 76:33-43, 1999.
  pubmed

• 5) Weaver LT, Walker WA:Uptake of macromolecules in the neonate. In human gastrointestinal development. (ed. Lebenthal E), Raven Press, New York, 1989, p731-748.

• 6) Harada E, Itoh Y, Sitizyo K, Takeuchi T, Araki Y et al:Characteristic transport of lactoferrin from the intestinal lumen into the bile via the blood in piglets. Comp Biochem Physiol A 124:321-327, 1999.

• 7) Talukder MJR, Takeuchi T, Harada E:Characteristics of lactoferrin receptor in bovine intestine:higher binding activity to the epithelium overlying Peyer's patches. J Vet Med A 50:123-131, 2003.

• 8) Kitagawa H, Yoshizawa Y, Yokoyama T, Takeuchi T, Talukder MJR et al. :Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs. J Vet Med Sci 65:567-572, 2003.
  pubmed

• 9) Takeuchi T, Kitagawa H, Harada E:Evidences of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats, Exp Physiol 89:263-270, 2004.

• 10) Kuwata H, Yamauchi K, Teraguchi S, Ushida Y, Toida T et al. :Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr 131:2121-2127, 2001.
  pubmed

• 11) Bollman JL, Cain JC, Grindlay JH:Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 33:1349-1352, 1948.
  pubmed

• 12) 原田悦守:新生仔腸管における高分子物質の取り込みとgut closure. 医学のあゆみ 198:959-964, 2001.

• 13) Kawakami H, Dosako S, Lonnerdal B:Iron uptake from transferrin and lactoferrin by rat intestinal brush-border membrane vesicles. Am J Physiol 258:G535-541, 1990.
  pubmed

• 14) Ziere GJ, Van Dijk MCM, Bijsterbosch MK, Van Berkel TJC:Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues. J Biol Chem 267:11229-11235, 1992.

• 15) Kuwata H, Ushida Y, Shimokawa Y, Toida T, Yamauchi K et al. :Digestion of orally administered lactoferrin in adult rats. In lactoferrin:structure, function and applications. (eds. Shimazaki K et al), Elsevier Science B. V. , Amsterdam, 2000, p311-317.

• 16) McAbee DD:Isolated rat hepatocytes acquire iron from lactoferrin by endocytosis. Biochem J 311:603-609, 1995.
  pubmed

P.128 掲載の参考文献

• 1) Takeuchi T, Kitagawa H. Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89:263-270, 2004.
  pubmed

• 2) Meredith C, Atkinson H:Development of methods to predict the allergenic potential of genetically modified foods and novel protein products. Toxicology 148:41-42, 2000.

• 3) Debbabi H, Dubarry M, Rautureau M, Tome D:Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 65:283-293, 1998.
  pubmed

• 4) Iigo M, Shimamura M, Matsuda E, Fujita K, Nomoto H et al. :Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa:a possible explanation for inhibition of carcinogenesis and metastasis. Cytokine 25:36-44, 2004.
  pubmed

• 5) Wakabayashi H, Takakura N, Yamauchi K, Tamura Y:Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 13:239-245, 2006.
  pubmed

• 6) Yamamoto S, Ishida T, Inoue A, Mikami J, Muraguchi M et al. :HEPC-based liposomes trigger cytokine release from peripheral blood cells:effects of liposomal size, dose and lipid composition. Int J Pharm 236:125-133, 2002.
  pubmed

P.133 掲載の参考文献

• 1) 厚生労働省健康政策局歯科衛生課・編:平成11年歯科 疾患実態調査報告. 口腔保険協会, 東京, 2001.

• 2) Miyauchi M, Sato S, Kitagawa S, Hiraoka M, Takata T:Cytokine expression in rat molar gingival periodontal tissues after topical application of lipopolysaccharide. Histochem Cell Biol 116:57-62, 2001.
  pubmed

• 3) Miyauchi M, Kitagawa S, Hiraoka M, Saito A, Takata T:Immunolocalization of CXC chemokine and recruitment of polymorphonuclear lcukocytes in the rat molar periodontal tissue after topical application of lipopolysaccharide. Histochem Cell Biol 121:291-297, 2004.
  pubmed

• 4) Zimecki M, Miedzybrodzki R, Szymaniec S:Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; correlation with decreased cytokine production. Arch Immunol Ther Exp (Warsz) 46:361-365, 1998.
  pubmed

• 5) Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A, Offord E:Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 296:261-266, 2002.
  pubmed

• 6) Ishikado A, Imanaka H, Kotani M, Fujita A, Makino T:Liposomal lactoferrin induced significant increase of the interferon-alpha (IFN-alpha) producibility in healthy volunteers. Biofactors 21:69-72, 2004.
  pubmed

• 7) Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T:Liposomalization of lactoferrin enhanced itls anti-inflammatory effects via oral administration. Biol Pharm Bull 28:1717-1721, 2005.

• 8) Troost FJ, Steijns J, Saris WH, Brummer RJ:Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr 131:2101-2104, 2001.
  pubmed

• 9) kerlund K, Erlandsson Harris H, Tracey KJ, Wang H, Andersson U:Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol 115:32-41, 1999.
  pubmed

• 10) Na YJ, Han SB, Kang JS, Yoon YD, Joe CO:Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. Int Immunopharmacol 4:1187-1199, 1996.

• 11) Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA. Mattsby-Baltzer I:Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220:83-95, 2002.
  pubmed

• 12) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89:263-70, 2004.
  pubmed

• 13) Kuhara T, Iigo M, Itoh T, Ushida Y, Tsuda H:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199, 2000.
  pubmed

• 14) Kuhara T, Yamauchi K, Tamura Y, Okamura H:Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res 26:489-499, 2006.
  pubmed

P.140 掲載の参考文献

• 1) Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K:Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 74:4137-4142, 1991.
  pubmed

• 2) Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M:Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1121:130-136, 1992.
  pubmed

• 3) Hwang PM, Zhou N, Shan X, Arrowsmith CH, Vogel HJ:Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288-4298, 1998.
  pubmed

• 4) Umeyama M, Kira A, Nishimura K, Naito A:Interactions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid state NMR. Biochim Biophys Acta 1758:1523-1528, 2006.
  pubmed

• 5) Van Dijck PW, De Kruijff B, Van Deenen LL, De Gier J, Demel RA:The preference of cholesterol for phosphatidylcholine in mixed phosphatidylcholine-phosphatidylethanolamine bilayers. Biochim Biophys Acta 455:576-587, 1976.
  pubmed

• 6) Matsuzaki K, Murase O, Fujii N, Miyajima K:Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming apore. Biochemistry 34:6521-6526, 1995.

• 7) Matsuzaki K:Why and how are peptide-lipid interactions utilized for self defence?. Biochem Soc trans 29:598-601, 2001.
  pubmed

• 8) Cullis PR, Hope MJ:Effects of fusogenic agent on membrane structure of erythrocyte ghosts and the mechanism of membrane fusion. Nature 271:672-674, 1978.
  pubmed

P.147 掲載の参考文献

• 1) 冨田信一, 清澤 功:ラクトフェリンによるビフィズス菌増殖促進作用. 必須アミノ酸研究 157:54-59, 1999.

• 2) Matsue M, Tomita S, Nyui S, Matsuyama J, Kiyosawa I:Suppressive effects of lactoferrin on bleomycin-dependent DNA damage by the iron ion and ascorbate. Biosci Biotechnol Biochem 58:67-71, 1994.

• 3) Kishore AR, Erdei J, Kalfas S, Forsgren A, Naidu AS:Detection of bacterial interaction with lactoferrin by an enzyme-linked ligand binding assay (ELBA). JMed Microbiol 37:341-345, 1992.

• 4) Tomita S, Hagiwara K, Matsuyama J, Kiyosawa I:Binding of lactoferrin to bacterial cells of the Clostridium species and their agglutination. Biosci Biotechnol Biochem 62:1471-1475, 1998.
  pubmed

• 5) Tomita S, Shirasaki N, Hayashizaki H, Matsuyama J, Benno Y et al. :Binding characteristics of bovine lactoferrin to the cell surface of Clostridium species and identification of the lactoferrin-binding Protein. Biosci Biotechnol Biochem 62:1476-1482, 1998.

• 6) Ben-Amor K, Breeuwer P Verbaarschot P, Rombouts FM, Akkermans ADL et al. :Multiparametric flow cytometry and cell sorting for the assessment of viable, injured, and dead Btfidobacterium cells during bile salt stress. Appl Environ Microbiol 68:5209-5216, 2002.

• 7) Recio I, Visser S:Antibacterial and binding characteristics of bovine, ovine and caprine lactoferrins:a comparative study. International Dairy J 10:597-605, 2000.

• 8) Kim WS, Tanaka T, Shimazaki K:Transferrin family proteins bind to Bifidobacterium spp. Milchwissenschaft 59:491-494, 2004.

P.153 掲載の参考文献

• 1) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. ミルクサイエンス 53(4):365-368, 2004.

• 2) Shimazaki K, Tanaka T, Kon H, Oota K, Kawaguchi A et aL:Separation and characterization of the Cterminal half molecule of bovine lactoferrin. J DairySci 76 (4):946-955, 1993.

• 3) Shimazaki K, Hosokawa T:Atentative method forrapid preparation of iron-saturated lactoferrin by affinity chromatography. Animal Sci Technol 62 (4):354-356, 1991.

• 4) Mazurier J, Spik G:Comparative study of the ironbinding properties of human transferrins. 1. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim Biophys Acta 629 (2):399-408, 1980.

• 5) Aisen P, Leibman A:Lactoferrin and transferrin:a comparative study. Biochim. Biophys Acta 257 (2):314-323, 1972.
  pubmed

• 6) Groves ML:The isolation of a red protein from milk. J Am Chem Soc 82 (13):3345-3350, 1960.

• 7) Laemmli UK:Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (5259):680-685, 1970.
  pubmed

• 8) Shimazaki K, Nam MS, Harakawa S, Tanaka T, Omata Y et al. :Monoclonal antibody against bovine lactoferricin and its epitopic site. J Vet Med Sci 58 (12):1227-1229, 1996.

• 9) 藤原三知雄, 川上 浩, 柳平修一, 大槻健蔵:ラクトフェリン結合性Protein(LF-BP)の生理機能. Foods Food Ingrad J Jpn 211(5):414-419, 2006.

• 10)Baveye S, Elass E, Mazurier J, Legrand D:Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS Lett 469 (1):5-8, 2000.

• 11) Anderson BF, Baker HM, Norris GE, Rumball SV, Baker EN:Apolactoferrin structure demonstrates ligand-induced conformationai change in transferrins. Nature 344 (6268):784-787, 1990.
  pubmed

• 12) van Veen HA, Geerts ME, van Berkel PH, Nuijens JH:The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur J Biochem 271 (4):678-684, 2004.

• 13) Takekawa H, Ina C, Sato R, Toma K, Ogawa H:Novel carbohydrate-binding activity of pancreatic trypsins to N-linked glycans of glycoproteins. J BiolChem 281 (13):8528-8538, 2006.

P.157 掲載の参考文献

• 1) 難波俊二, 石井利明, 奥田優子, 加藤弘子, 盛田俊介:ラテックス凝集比濁法によるヒトおよびウシラクトフェリン測定試薬の開発. FFI JOURNAL 211 (5):387-397, 2006.

• 2) 石井利明, 難波俊二, 奥田優子, 佐野将也, 芳野 原:感染症による好中球絶対数変動と血中ラクトフェリン値の関係について. 医学検査 52(8):1053-1057, 2003.
  Medical*Online

• 3) 石井利明, 難波俊二, 奥田優子, 佐野将也, 盛田俊介:感染症における血中ラクトフェリン測定の有用性について. Milk Science 53(4):232-234, 2004.

• 4) 石井利明, 難波俊二, 奥田優子, 佐野将也, 芳野 原:好中球の空胞(貧食)細胞の観点から考察した血中ラクトフェリンの変動について. 医学検査 54(3)214-219, 2005.

• 5) Kuhara T. ligo M lto T, Ushida Y, Sekine K et al:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL18 in the intestinal epithetlium. Nutr Cancer 38 (2):192-199, 2000.

• 6) Takakura N, Wakabayashi H, Yamauchi K, Takase M:Influences of orally administered lactoferrin on lFN-y and IL-10 production by intestinal intraepithelial lyrnphocytes and mesenteric lymph-node cells. Biochem Cell Biol 84:363-368, 2006.

• 7) Takeuchi T, Kitagawa H, Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89 (3):263-270, 2004.
  pubmed

• 8) Harada E, Araki Y, Furumura E, Takeuchi T, Sitizyo K et al:Characteristic transfer of colostrum-derived biologically active substances into cerebrospinal fluid via blood in natural suckling neonatal pigs. J Vet Med A 49:358-364, 2002.

• 9) Kuhara T, Yamauchi K, Tamura Y, Okamura H:Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL18 and type I IFN in the small intestine. Infection Cytokine Res 26 (7):489-499, 2006.

P.161 掲載の参考文献

• 1) Sikorska MHJ et al. :The relationship between the levels of SigA, lactoferrin and a1 proteinase inhibitor in saliva and permanent dentition caries in 12-year-olds. Oral Micro and Immun 17:272-276, 2002.

• 2) Fine DH et al. :Lactoferrin iron levels are reduced in saliva of patients with localized aggressive periodontitis. J Periodontol 73:624-630, 2002.
  pubmed

• 3) Jentsch H et al. :Lactoferrin and other markers from gingival crevicular fluid and saliva before and after periodontal treatment. J Clin Periodontol 31:511-514, 2003.

• 4) Jezequel N et al. :Salivary lactoferrin in primary Sjogren's syndrome. Clin Exp Rheumatol 7:123-125, 1989.
  pubmed

• 5) Haghighat N, al-Hashimi I:The status of lactoferrin and total binding capacity of human parotid saliva in Sjogren's syndrome. Clin Exp Rheumatol 21:485-488, 2003.

• 6) Tanida T et al:Influence of aging on candidal growth and adhesion regulatory agents in saliva. J Oral Pathol Mcd 30:328-335, 2001.

• 7) Tanida T et al:Decreased excretion of anti-microbial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med 32:586-594, 2003.

P.165 掲載の参考文献

• 1) Behrman RE, Kliegman RM, Jenson HB:Nelson text book of pediatrics 17th edition. Saunders, Philadelphia, 2004, p1081-1083.

• 2) Morinaga Milk Industry Co. Ltd:Nutritional science laboratory. Biology functions of lactoferrin: basic research and applications. Fourth edition. 2003, p1-17.

• 3) Levay PF, Viljoen M:Lactoferrin:ageneral review. Haematologica 80:252-267, 1995.

• 4) van der Strate BWA, Beljaars L, Molema G, Harmsen MC, Meijer DKF:Antiviral activities of lactoferrin. Antiviral Res 52:225-239, 2001.

• 5) Moriuchi M, Moriuchi H:Amilk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 166:4231-4236, 2001.
  pubmed

• 6) Ishii K, Takamura N, Shinohara M, Wakui N, Shin H, Sumino Y et al. :Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12months. Hepatol Res 25:226-233, 2003.

• 7) Yamauchi K, Hiruma M, Yamazaki N, Wakabayashi H, Kuwata H, Teraguchi S et al. :Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43:197-202, 2000.
  pubmed

• 8) Superti F, Ammendolia MG, Valenti P, Seganti L:Antirotavial activity of milk proteins:lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol 186:83-91, 1997.
  pubmed

• 9) Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, Antonini G:Involvement of lactoferrin mentasaturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochem Biophys Acta 1528:107-115, 2001.
  pubmed

• 10) Seganti L, Di Biase AM, Marchetti M, Pietrantoni A, Tinari A, Superti F:Antiviral activity of lactoferrin towards naked viruses. BioMetals 17:295-299, 2004.
  pubmed

• 11) Pando V, Isa P, Arias CA, Lopez S:Influence of calcium on the early steps of rotavirus infection. Virology 295:190-200, 2002.

• 12) Masson PL, Heremans JF:Lactoferrin in milk from different species. Comp Biochem Physiol 39B:119-129, 1971.

• 13) Levay PF, Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

P.168 掲載の参考文献

• 1) Baker EN, Baker HM, Kidd RD:Lactoferrin and transferring:functional variations on a common structural framework. Biochem Cell Biol 80:27-34, 2002.

• 2) Nagasako Y, Saito H, Tamura Y, Shimamura S, Tomita M:lron-binding properties of bovine lactoferrin in iron-rich solution. J Dairy Sci 76:1876-1881, 1993.

• 3) Kawakami H, Dosako S, Nakajima I:Effect of lactoferrin on iron solubility under neutral conditions. B iosci. Biotech. Biochem 57:1376-1377. 1993.

• 4) Uchida T, Oda T, Sato K, Kawakami H:Availability of lactoferrin as a natural solubilizer of iron for food products. Inter Dairy J 16:95-101, 2006.

P.174 掲載の参考文献

• 1) Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M et al. :Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 66:486-91, 1998.
  pubmed

• 2) 藤原 純, 中島啓介, 杉村典彦, 小林孝雄, 小鷲悠典:歯周ポケットにおけるラクトフェリンの分布に関する研究. 日歯保存誌 47:411-419, 2004.
  Medical*Online

• 3) Wong B, Lumma WC, Smith AM. Sisko JT, Wright SD et al. :Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 69:959-962, 2001.
  pubmed

• 4) Sunil DA:The interaction of lipid A and lipopolysaccharide with human serum albumin. Endotoxin in health and disease. (eds. Brade H, Opal SM, Vogel SN), Morrison DC. Marcel Dekker, Inc. , New York, 1999, p413-422.

• 5) 湯本泰弘, 中島啓介, 藤原 純, 池田雅美, 小鷲悠典:ヒトラクトフェリンがヒト単球系細胞のケモタキシスに与える影響. 東日本歯誌 23:53-60, 2004.

• 6) Antal-Szalmas P, Strijp JA, Weersink AJ, Verhoef J, Van Kessel KP:Quantitation of surface CDI40n human morlocytes and neutrophils. J Leukoc Biol 61:721-728, 1997.
  pubmed

• 7) Klesius PH, Chambers WH, Schultz RD:Effect of bacterial lipopolysaccharide on bovine polymor-phonuclear neutrophil migration in vitro. Vet Immunol Immunopathol 7:239-44, 1984.

P.179 掲載の参考文献

• 1) Lima MF, Kierszenbaum F:Lactoferrin effects on phagocytic cell function. J Immunol 139:1647-1651, 1987.
  pubmed

• 2) Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA et al:Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 281:G1140-1150, 2001.
  pubmed

• 3) Matsumoto A, Yoshida H, Takahashi S, Kobata A:Structural study of the sugar chains of human lactoferrin:finding of four novel complex-type asparagine-linked sugar chains. J Biochem 91:143-155, 1982.

• 4) Eda S. Kikugawa K, Beppu M:Binding characteristics of human lactoferrin to the human monocytic leukemia cell line THP-1 differentiated into macrophages. Biol Pharm Bull 19:167-175, 1996.

• 5) Pahl HL:Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866, 1999.

• 6) Hayden MS, Ghosh S:Signaling to NF-kappaB. Genes Dev 18:2195-2224, 2004.
  pubmed

• 7) Bonizzi G, Karin M:The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288, 2004.
  pubmed

• 8) Diaz-Guerra MJ, Velasco M, Martin-Sanz P, Bosca L:Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes. Requirement of NF-kappaB activation after stimulation with bacterial cell wall products and phorbol esters. J Biol Chem 271:30114-30120, 1996.
  pubmed

P.182 掲載の参考文献

• 1) Siebert PD, Huang BC:Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci U S A 94:2198-2203, 1997.
  pubmed

• 2) Liu D, Wang X, Zhang Z, Teng CT:An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochem Biophys Res Commun 301:472-479, 2003.
  pubmed

• 3) Benaissa M, Peyrat JP, Hornez L, Mariller C, Mazurier J et al. :Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer 114:299-306, 2005.
  pubmed

• 4) Panella TJ, Liu YH, Huang AT, Teng CT:Polymorphism and altered methylation of the lactoferrin gene in normal leukocytes, leukemic cells, and breast cancer. Cancer Res 51:3037-3043, 1991.
  pubmed

• 5) Liu LH, Gladwell W, Teng CT:Detection of exon polymorphisms in the human lactoferrin gene. Biochem Cell Biol 80:17-22, 2002.
  pubmed

• 6) Teng C, Gladwell W, Raphiou I, Liu E:Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals 17:317-323, 2004.
  pubmed

• 7) Breton M, Mariller C, Benaissa M, Caillaux K, Browaeys E et al. :Expression of delta-lactoferrin induces cell cycle arrest. Biometals 17:325-329, 2004.
  pubmed

• 8) Goldberg GS, Kunimoto T, Alexander DB, Suenaga K, Ishidate F et al. :Full length and delta lactoferrin display differential cell localization dynamics, but do not act as tumor markers or significantly affect the expression of other genes. Med Chem 1:57-64, 2005.
  pubmed

• 9) Mariller C, Benaissa M, Breton M, Hardiville S, Pradelle G et al:Human delta-lactoferrin is a transcription factor which enhances Skp1 (S-phase kinase associated protein) gene expression. FEBS J 2007, (in press).

• 10) Baker EN, Baker HM, Kidd RD:Lactoferrin and transferrin:functional variations on a common structural framework. Biochem Cell Biol 80:27-34, 2002.
  pubmed

• 11) Son KN, Park J, Chung CK, Chung DK, Yu DY et al. :Human lactoferrin activates transcription of IL-1beta gene in mammalian cells. Biochem Biophys Res Commun 290:236-241, 2002.
  pubmed

• 12) Baker EN, Baker HM:Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 62:2531-2539, 2005.
  pubmed

• 13) He J, Furmanski P:Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721-724, 1995.
  pubmed

• 14) Hart GW, Greis KD, Dong LY, Blomberg MA, Chou TY et al. :O-linked N-acetylglucosamine:the "yinyang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Adv Exp Med Biol 376:115-123, 1995.
  pubmed

• 15) Hart GW, Kreppel LK, Comer FL Arnold CS, Snow DM et al. :O-GlcNAcylation of key nuclear and cytoskeletal proteins:reciprocity with Ophosphorylation and putative roles in protein multimerization. Glycobiology 6:711-716, 1996.

• 16) Krek W:Proteolysis and the G1-S transition:the SCF connection. Curr Opin Genet Dev 8:36-42, 1998.
  pubmed

• 17) Ang XL, Wade Harper J:SCF-mediated protein degradation and cell cycle control. Oncogene 24:2860-2870, 2005.
  pubmed

• 18) Piva R, Liu J, Chiarle R, Podda A, Pagano M et al:In vivo interfererlce with Skpl function leads to genetic instability and neoplastic transformation. Mol Cell Biol 22:8375-8387, 2002.

• 19) Lehmann A, Toda T:Fission yeast Skpl is required for spindle morphology and nuclear membrane segregation at anaphase. FEBS Lett 566:77-82, 2004.

• 20) Ward PP, Paz E, Conneely OM:Multifunctional roles of lactoferrin:acritical overview. Cell Mol Life Sci 62:2540-2548, 2005.

P.190 掲載の参考文献

• 1) Levay PF, Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 2) Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M et al. :ldentification of a lactoferrin derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278:10162-10173, 2003.

• 3) Hutchens TW, Henly JF, Yip TT et al. :Structurally intact (78-kDa) forms of maternal lactoferrin purified from urine of preterm infants fed human milk:identification of trypsin-like proteolytic cleavage event in vivo that does not result in fragment dissociation. Proc Natl Acad Sci USA 88:2994-2998, 1991.

• 4) Tanaka K, Ikeda M, Nozaki A et al. :Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C:a pilot study. Jpn J Cancer Res 90:367-371, 1999.
  pubmed

• 5) Ishii K, Takamura N, Shinohara M et al. :Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25 (3):226-233, 2003.
  pubmed

• 6) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898:1980.

• 7) van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK:Antiviral activities of lactoferrin. Antiviral Res 52:225-239, 2001.
  pubmed

• 8) Brock J:Lactoferrin:amultifunctional immunoregulatory protein? Immunol Today 16:417-419, 1995.

• 9) Cohen MS, Mao J, Rasmussen GT, Serody JS, Britigan BE:Interaction of lactoferrin and lipopolysaccharide (LPS):effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation, J Infect Dis 166:1375-1378, 1992.
  pubmed

• 10) Hagiwara T et al. :Effects of lactoferrin on iron absorption in immature mice. Nutrition Research 17:895-906, 1997.

• 11) Bonkovsky HL, Banner BF, Rothman AL:Iron and chronic viral hepatitis. Hepatology 25:759-768:1997.

• 12) Olynyk JK:Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hcpatitis C. Gastroenterology 108:1104-1109:1995.

• 13) Okada S, Tanaka K, Sato T et al. :Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93 (9):1063-1069, 2002.
  pubmed

• 14) Iwasa M, Kaito M, Ikoma J et al:Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype lb. Am J Gastroenterol 97(3):766-767, 2002.

• 15) Hirashima N, Orito E, Ohba K et al. :A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype lb and high viral load. Hepatol Res 29(1):9-12, 2004.
  pubmed

• 16) Ishibashi Y, Takeda K, Tsukidate N et al:Randomized placebocontrolled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 32 (4):218-223, 2005.

• 17) Kuhara T et al:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199, 2000.
  pubmed

• 18) 堀江義則, 日比紀文, 石井裕正:肝疾患と酸化ストレス. 日消誌 103:789-796, 2006.
  Medical*Online

• 19) Ishii K, Sumino Y, Higami K:Long-term follow-up of chronic hepatitis C patients after oral lactoferrin administration. Food function 3(1):1-6, 2007.

P.194 掲載の参考文献

• 1) 小畑孝四郎:月経痛. Nippon Rinsho 59:1762-1767, 2001.

• 2) 堤 治:子宮内膜症と環境因子. 産婦人科治療 83:471-475, 2001.
  Medical*Online

• 3) 原田悦守, 竹内 崇:ミルク含有ラクトフェリンの体内移行とその新規多様機能の発見. 医学のあゆみ 218:396-402, 2006.
  Medical*Online

• 4) 望月良美:月経痛に対する新たな対処法の開発-使い捨てカイロによる三陰交刺激の有効性の検討. 埼玉医科大学短期大学紀要埼玉医科大学短期大学紀要 12:59-65, 2001.

• 5) 金丸みはる:低用量経口避妊薬使用経験-月経困難症を訴える女性のQOLの観点からの考察-. 産科と婦人科 70:406-411, 2003.

• 6) 上田多美:月経困難症. Hormone frontier in gynecology 2:161-165, 2004.
  Medical*Online

• 7) 柳沼 つとむ:母子の臨床薬理学. 母子の健康科学. (青木 康子・編), 日本看護協会出版会, 東京, 2000, p269-299.

• 8) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. AmJ Physiol 285:306-312, 2002.

P.199 掲載の参考文献

• 1) Takada Y, Kobayashi N, Kato K, Matsuyama H, Yahiro M et al:Effects of whey protein on calcium and bone metabolism in ovariectomized rats. J Nutr Sci Vitaminol 43:199-210, 1997.
  pubmed

• 2) Toba Y, Takada Y, Yamamura J, Tanaka M, Matsuoka Y et al. :Milk basic protein:a novel protective function of milk against osteoporosis. Bone 27:403-408, 2000.
  pubmed

• 3) 島崎敬一:ラクトフェリンの多機能性を活用するために. FFIジャーナル 211:383-386, 2006.

• 4) Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A et al. :Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. BBRC 296:261-266, 2002.
  pubmed

• 5) Cornish J, Callon KE, Naot D, Palmano KP, Banovic Tet al:Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrine Society 145:4366-4374, 2004.

• 6) Cornish J:Lactoferrin promotes bone growth. BioMetals 17:331-335, 2004.
  pubmed

• 7) Naot D, Grey A, Reid R, Cornish J:Lactoferrin-a novel bone growth factor. Clinical Medicine & Research 3:93-101, 2005.

• 8) Cornish J, Palmano K Callon KE, Watson M, Lin JM et al. :Lactoferrin and bone:structure-activity relationships. Biochem Cell Biol 84:297-302, 2006.
  pubmed

• 9) Nomura Y, Oohashi K, Watanabe M, Kasugai S:Increase in bone mineral density through oral administration of shark gelatin to ovariectomized rats. Nutrition 21:1120-1126, 2006.

• 10) Termine JD, Belcourt AB, Kleinman HK:Mineral and collagen-binding proteins of fetal calf bone. J Biol Chem 256:10403-10408, 1981.

• 11) Laemmli UK:Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970.
  pubmed

• 12) Kuhara T, Yamauchi K, Tamura Y, Okamura H:Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon & Cytokine Research 26:489-499, 2006.

• 13) Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T:Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 15:541-549, 2000.

P.204 掲載の参考文献

• 1) Kalfas S, Andersson M, Edwardsson S, Forsgren A, Naidu AS:Human lactoferrin binding to Porphyromonas gingivalis, Prevotella intermedia and Prevotella melaninogenica. Oral Microbiol Immunol 6:350-355, 1991.
  pubmed

• 2) Shi Y, Kong W, Nakayama K:Human lactoferrin binds and removes the hemoglobin receptor protein of the periodontopathogen Porphyromonas gingivalis. J Biol Chem 275:30002-30008, 2000.
  pubmed

• 3) Silness J, Leo H:Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22:121-135, 1964.

• 4) Loe H, Silness J:Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 21:533-551, 1963.
  pubmed

• 5) Ashimoto A, Chen C, Bakker I, Slots J:Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol 11:266-273, 1996.
  pubmed

• 6) 松尾忠行, 伊豆丸美恵, 松瀬亮一, 埴岡 隆:歯肉辺縁部に貯留する炎症性物質はライフスタイル因子と関連する. 口腔衛生会誌 56:269-280, 2006.

P.209 掲載の参考文献

• 1) Brock J:Lactoferrin:a multifunctional immunore gulatory protein? Immunol Today 16:417-419, 1995.

• 2) Hayashida K et al. :Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.
  pubmed

• 3) 原田悦守, 竹内 崇:ミルクに含まれるラクトフェリンの脳内移行とその新規鎮痛作用. ペインクリニック 26:359-368, 2005.

• 4) Hayashida K et aL:Lactoferrin enhances peripheral opioid-mediated anticiception via nitric oxide in rats. Eur J Pharmacol 484:175-181, 2004.
  pubmed

• 5) Hayashida K et al. :Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. Am J physiol Regul Integr Comp Physiol 285:R306-R312, 2004.

• 6) Orsi N:The antimicrobial activity of lactoferrin:Current status and perspectives. Bio Metals 17:189-196, 2004.

• 7) 佐藤保, 佐藤れえ子:口内炎および歯周炎に対するラクトフェリン応用の臨床的評価. 日本歯科保存学会講演, 1996.

• 8) Fishman JB:Receptor-mediated transcytosis of transferring across the blood-brain barrier. J Neurosci Res 18:299-304, 1987.

• 9) Ishikado A et al:Liposomal lactoferrin induced significant increase of the interferon-alpha(IFN-alpha) producibility in healthy volunteers. Biofactors 21(1-4):69-72, 2004.
  pubmed

• 10) Maeda Ji B et al. :Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci, 2005, Epub ahead of print).

P.213 掲載の参考文献

• 1) Singh PK, Parsek MR, Greenberg EP, Welsh MJ:A component of innate immunity prevents bacterial biofilm development. Nature 417(6888):552-555, 2002.
  pubmed

• 2) Banin E, Vasil ML, Greenberg EP:Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA 102(31):11076-11081, 2005.
  pubmed

• 3) Hayashida K, Takeuchi T, Harada E:Lactoferrin enhances peripheral opioid-mediated antinociception via nitric oxide in rats. Eur J Pharmacol 484(2-3):175-181, 2004.

• 4) Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Harada E:Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66(2):149-154, 2004.
  pubmed

P.219 掲載の参考文献

• 1) 原田悦守:ミルク由来ラクトフェリンの体内移行動態とその新規作用-抗ストレス, 鎮痛, 抗炎症作用-. 慢性疼痛 23(1):9-22, 2004.

P.225 掲載の参考文献

• 1) 大谷 元, 鴇田文三郎:乳清中の感染防御関連たんぱく質の科学. 乳技協資料 37:10-23, 1987.

• 2) 尾形朋宏, 寺口 進, 早澤宏紀:ラクトフェリンのマウス腸内細菌叢調節作用. Milk Science 46:233-238, 1997.

• 3) 角田 出:ラクトフェリンによるストレス軽減および生体防御活性増強-魚類への投与効果-. バイオインダストリー 15:23-33, 1998.

• 4) Kakuta I:Reduction of stress response in carp, Cyprinus carpio L. , held under deteriorating enviromental conditions, by oral administration of bovine lactoferrin. J Fish Diseases 21:161-167, 1998.

• 5) van't Land B, van Beek NMA, van den Berg JJM, M'Rabet L:Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Digestive Diseases Sci 49:425-433, 2004.

• 6) 角田 出:ラクトフェリンの投与がニジマスの非特異的生体防御活性に及ぼす影響. 石巻専修大学研究紀要 8:53-57, 1997.

• 7) Cowan ST, Steel KJ:Cowan and Steel's manual for the identification of medical bacteria. 3rd ed. (eds. Barrow GI, Felthan RKA), Cambridge Univ. Pres, London, 2003.

• 8) Buchanan RE, Cibbons NE:Bergey's manual of determinative bacteriology. 8th ed. The Williams and Wilkins Co. Baltimore, 1974.

• 9) 湯川修身:放射線抵抗性の誘導. 1. 活性酸素とその防御機構. (色田幹雄, 山田 武・編), 放射線医学総合研究所, 千葉, 1992, p5-13.

• 10) 増田康治・編:放射線生物学. 南山堂, 東京, 2002, p5-125.

• 11) Sato R, Inanami O, Tanaka Y, Takase M, Naito Y:Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus(FIV)-positive and FIV-negative cats. Am J Vet Res 57:1443-1446, 1996.

P.230 掲載の参考文献

• 1) 新田和男:癌化学療法の現状と展望. 有機合成化学 49:968-979, 1991.

• 2) Artym J, Zimecki M, Kruzel L:Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice. Anticancer Res 24:3831-3836, 2004.

• 3) van't Land B, van Beek NM, van den Berg JJ, M'Rabet L:Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Dig Dis Sci 49:425-433, 2004.

• 4) Artym J, Zimecki M, Kruzel M:Normalization of peripheral blood cell composition by iactoferrin in cyclophosphamide-treated mice. Med Sic Monit 10:BR 84-89, 2004.

• 5) Bartal L, Padeh S, Passwell JH:Lactoferrin inhibits prostaglandin E2 secretion by breast milk macrophages. Pediatric Res 21:54-57, 1987.

• 6) 角田 出:ラクトフェリンの投与がニジマスの非特異的生体防御活性に及ぼす影響. 石巻専修大学研究紀要 8:53-57, 1997.

• 7) 角田 出, 黒倉 寿, 中村浩彦, 山内恒治:ラクトフェリン投与によるマダイ体表粘液の非特異的生体防御活性の増強. 水産増殖 44:197-202, 1996.

• 8) Lima MF, Kierszenbaum F:Lactoferrin effects of phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. J Immunol 139:1647-1651, 1987.

• 9) 尾形朋宏, 寺口 進, 早澤宏紀:ウシラクトフェリンのマウス腸内細菌叢調節作用. Milk Science 46:233-238, 1997.

P.236 掲載の参考文献

• 1) Wakabayashi H, Uchida K, Yamauchi K, Teraguchi S, Hayasawa H et al. :Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J Antimicrob Chemother 46:595-601, 2000.
  pubmed

• 2) Takakura N, Wakabayashi H, Ishibashi H, Teraguchi S, Hayasawa H et al. :Oral lactoferrin treatment of experimental oral candidiasis in mice. Antirnicrob Agent Chemother 47:2619-2623, 2003.

• 3) 津田洋幸, 関根一則, 飯郷正明:ラクトフェリンによる発がん予防とその機序の解析. FFI Journal 200:27-35, 2002.

• 4) Yamauchi K, Hiruma M, Yamazaki N, Wakabayashi H, Kuwata H et al. :Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43:197-202, 2000.
  pubmed

• 5) Iwasa M, Kaito M, Ikoma J, Takeo M, Imoto I et al. :Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype lb. Am J Gastroenterol 97:766-777, 2002.

• 6) Kuhara T, Yamauchi K, Tamura Y, Okamura H:Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interf Cytok Res 26:489-499, 2006.

• 7) 宮地一裕:予防食の観点からのヨーグルト. アクティブシニア社会の食品開発指針. (津志田藤二郎・他・ 編), サイエンスフォーラム, 2006, p77-83

• 8) 岩淵紀介, 高橋典俊, 清水(肖)金忠, 宮地一裕, 岩附 慧二:Bifidobacterium longum BB536の樹状細胞を介した免疫応答について. 2006年日本農芸化学会.

P.242 掲載の参考文献

• 1) 中元秀友, 小滝周二, 菅野義彦・他:高齢者の難治性腹膜炎発症に関与する背景因子はなにか. 腎と透析 57 別冊 腹膜透析 2004:302-305, 2004.

• 2) Keane WF, Alexander SR, Bailie GR et al. :Peritoneal dialysis-related peritonitis treatment recommendations. Perit Dial Int 16:557-573, 1996.
  pubmed

• 3) Levay PF et al. :Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 4) 石井利明, 難波俊二, 奥田優子, 佐野将也, 盛田俊介:感染症における血中ラクトフェリン測定の有用性について. Milk Science 53(4):232-234, 2004.

• 5) 石井利明, 難波俊二, 奥田優子, 佐野将也, 芳野 原:好中球の空砲(貧食)細胞の観点から考察した血中ラクトフェリンの変動について. 医学検査 54(3):213-219, 2005.

• 6) 難波俊二, 石井利明, 奥田優子, 加藤弘子, 鈴木徳二, 盛田俊介:ラテックス凝集法によるヒトおよびウシラクトフェリン測定試薬の開発. Milk Science 211(5):387-396, 2006.

P.248 掲載の参考文献

• 1) Caccavo D, Afeltra A, Pece S et al. :Lactoferrin-lipid A-lipopolysaccharide interaction:inhibition by anti-human lactoferrin monoclonal antibody AGM 10. 14. Infect Immun 67(9):4668-4672, 1999.
  pubmed

• 2) Kijlstra A:The role of lactoferrin in the nonspecific immune response on the ocular surface. Reg Immunol 3(4):193-197, 1990-1991.

• 3) Sanchez L, Calvo M, Brock JH:Biological role of lactoferrin. Arch Dis Child 67(5):657-661, 1992.
  pubmed

• 4) Tenovuo J, Lehtonen OP, Aaltonen AS, Vilja P, Tuohimaa P:Antimicrobial factors in whole saliva of human infants. Infect Immun 51(1):49-53, 1986.
  pubmed

• 5) Brock J:Lactoferrin:amultifunctional immunore-gulatory protein? Immunol Today 16(9):417-419, 1995.

• 6) Nishiya K, Horwitz DA:Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity. J Immun 129 (6):2519-2523, 1982.
  pubmed

• 7) Yamauchi K, Wakabayashi H, Hashimoto S et al. . Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265, 1998.
  pubmed

• 8) Ishibashi Y, Takeda K, Tsukidate N et al. Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 32(4):218-223, 2005.
  pubmed

• 9) Nozaki A, Ikeda M, Naganuma A:Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278(12):10162-10173, 2003.
  pubmed

• 10) Miehlke S, Reddy R, Osato MS et al:Direct activity of recombinant human lactoferrin against Helicobacter pylori. Journal of Clinical Microbiology 34(10):2593-2594, 1996.
  pubmed

• 11) Zullo A, De Francesco V, Scaccianoce G, Hassan C, Panarese A:Quadruple therapy with lactoferrin for Helicobacter pylori eradication:a randomized, multicentre study. Dig Liver Dis 37(7):496-500, 2005.
  pubmed